Atherosclerosis: From Subclinical Diagnosis to Interventional Treatment 2024
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".
Deadline for manuscript submissions: 30 June 2025 | Viewed by 49
Special Issue Editors
Interests: atherosclerosis; cardiovascular diseases; thrombosis; cardiovascular prevention; coronary intervention; antithrombotic drugs; dyslipidemia
Special Issues, Collections and Topics in MDPI journals
Interests: atherosclerosis; cardiovascular diseases; echocardiography; vascular ultrasound; coronary syndromes; dyslipidemia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Atherosclerosis is still the main factor in the development of cardiovascular diseases (CVDs). Although major improvements have been made in recent decades in both detection and treatment, the incidence of atherosclerotic CVD remains high. Despite major and continuous research in this domain, there remains a great demand and potential for improving atherosclerosis diagnosis and finding the right treatment options.
Starting from early childhood with primordial CVD prevention and trying to find different markers for early diagnosis, detecting atherosclerosis from subclinical stages remains important for deciphering the puzzle of early CVDs. Multiple imagistic and biological parameters have been assessed and followed for prognostic value, but few have been confirmed.
In time, atherosclerosis reaches clinical manifestations. This is the stage when many patients realize the clinical burden of atherosclerosis, as primary prevention has failed. Modern medication has a major role in chronic and acute CVD events, starting with antiplatelet drugs, modern variants of lipid-lowering drugs, anticoagulants for specific cardiac comorbidities, and finally, heart-failure therapies. All these drug regimens can be further improved to offer maximal benefit.
Finally, interventional treatment in atherosclerosis has sustainably evolved to offer, along with medical treatment, the best prognosis for patients.
Although it is a broad domain, atherosclerosis, from early detection to treatment, has much to offer to the research community. We invite you to address some of the issues related to these threatening CVD events and share your research to support finding the best current solutions for improving the lives of our patients.
Dr. Ovidiu Mitu
Dr. Lucia Stefania Magda
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- atherosclerosis
- diagnosis
- markers
- subclinical atherosclerosis
- cardiovascular prevention
- interventional treatment
- coronary syndromes
- antiplatelet
- anticoagulant
- lipid-lowering drugs
